Search results
Found 12418 matches for
Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
Sign up to our newsletter
Sign up to our newsletter to receive the latest news, insights and events directly to your inbox.
Join our research community
Join the Restore-B research community for breast reconstruction